Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Artiva Biotherapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT05917990 | Dyadic Text-Messaging Micro-Intervention | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05634525 |
| Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients |
| withdrawn |
| Phase 1 |
| 0 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jul 25, 2025 |
| clinicaltrials |
| NCT04571710 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT06572189 | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma | withdrawn | Early Phase 1 | 0 | Shanghai Changzheng HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06707896 | TCR1020-CD8 T Cells in KRAS-mutated Cancers | withdrawn | Phase 1 | 0 | University of PennsylvaniaOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT05067842 | Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma(TRACT DNA) | withdrawn | — | 0 | Medical College of WisconsinOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06592664 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC(FORTIFIDE) | withdrawn | Phase 1 / Phase 2 | 0 | Lisata Therapeutics, Inc.INDUSTRY | 0 | Jun 6, 2025 | clinicaltrials |
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | withdrawn | — | 0 | ProgenaBiomeOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05287347 | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort | withdrawn | — | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06895577 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer- | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT03879811 | Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | May 15, 2025 | clinicaltrials |
| NCT02414100 | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | withdrawn | Phase 1 | 0 | Orion Biotechnology Polska Sp. z o.o.INDUSTRY | 0 | Apr 9, 2025 | clinicaltrials |
| NCT01372696 | Endoscopic Characteristics of Colonic Tumours(C-LST) | withdrawn | N/A | 0 | Professor Michael BourkeOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT03636607 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma | withdrawn | N/A | 0 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Tarus Therapeutics, Inc.INDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT06144827 | A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | withdrawn | N/A | 0 | Montefiore Medical CenterOTHER | 0 | Mar 18, 2025 | clinicaltrials |
| NCT05584540 | UNTIRE: Cancer-related Fatigue With Digital Treatment | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03169777 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | withdrawn | Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04863430 | Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach | withdrawn | Phase 2 | 0 | Peking UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05296005 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | withdrawn | Phase 1 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Feb 7, 2025 | clinicaltrials |
| NCT05158374 | Molecular Effects of Aspirin & Metformin on Colonic Epithelium | withdrawn | N/A | 0 | University of EdinburghOTHER | 0 | Feb 6, 2025 | clinicaltrials |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | withdrawn | — | 0 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02853500 | Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies | withdrawn | Phase 4 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03764137 | Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer(Panitumumab) | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 0 | Jan 31, 2025 | clinicaltrials |
| NCT06341647 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | withdrawn | Phase 1 | 0 | GC Cell CorporationINDUSTRY | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06206876 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT05861336 | GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer(OVERPASS) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04093557 | Improving Outpatient Colonoscopy Bowel Prep With the Orton Score | withdrawn | N/A | 0 | University of VirginiaOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03802747 | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | withdrawn | Phase 1 | 0 | University of Colorado, DenverOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT05427344 | Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients | withdrawn | N/A | 0 | Tel Aviv UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona | withdrawn | N/A | 0 | University of ArizonaOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Nov 21, 2024 | clinicaltrials |
| NCT03228043 | Apatinib for Resectable Colorectal Cancer | withdrawn | N/A | 0 | Nanchong Central HospitalOTHER_GOV | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06017297 | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma(ESR-22-21719) | withdrawn | Phase 2 | 0 | Georgetown UniversityOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT01847495 | Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT04258969 | Pedaling at a Low-Moderate Intensity During Chemotherapy Administration | withdrawn | N/A | 0 | Rush University Medical CenterOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05518032 | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT04488159 | Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer(iMAGINE) | withdrawn | Phase 3 | 0 | Johannes Laengle, MD, PhDOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02745197 | A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer | withdrawn | Phase 2 | 0 | University of AlbertaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 30, 2025source: clinicaltrials